Athenex (OTCPK:ATNX.Q) - 주가, 뉴스 및 분석

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

ATNX.Q 주식 개요

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer.

회사 소개

ATNX.Q 기본 분석
눈송이 점수
가치 평가	2/6
미래 성장	0/6
과거 실적	0/6
재무 상태	0/6
배당금	0/6

보상

위험 분석

의미 있는 시가총액이 없습니다. ( $132K )

마이너스 주주 지분

최근 3개월간 주가 변동폭 심해

지난 5년간 매년 수익이 7.6% 씩 감소했습니다.

+ 1 더 많은 위험

Athenex, Inc. 경쟁사

Peak Bio

OTCPK:PKBO

US$198.9k

Acorda Therapeutics

OTCPK:ACOR.Q

US$316.7k

Athersys

OTCPK:ATHX.Q

US$185.2k

Endonovo Therapeutics

OTCPK:ENDV

US$595.2k

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Athenex
과거 주가
현재 주가	US$0.015
52주 최고치	US$6.00
52주 최저치	US$0.0003
베타	0.79
11개월 변경	52.00%
3개월 변경 사항	-86.19%
1년 변경 사항	-99.72%
33년 변화	-99.99%
5년 변화	-99.99%
IPO 이후 변화	-99.99%

최근 뉴스 및 업데이트

Recent updates

These Analysts Just Made A Sizeable Downgrade To Their Athenex, Inc. (NASDAQ:ATNX) EPS Forecasts

Mar 06

Have Insiders Been Buying Athenex, Inc. (NASDAQ:ATNX) Shares?

Feb 19

When Can We Expect A Profit From Athenex, Inc. (NASDAQ:ATNX)?

Jan 29

주주 수익률

	ATNX.Q	US Biotechs	US 마켓
7D	0%	-0.009%	0.5%
1Y	-99.7%	9.8%	23.9%

수익률 대 산업: ATNX.Q 지난 1년 동안 6.7 %를 반환한 US Biotechs 업계보다 저조한 성과를 냈습니다.

수익률 대 시장: ATNX.Q 지난 1년 동안 23.3 %를 반환한 US 시장보다 저조한 성과를 냈습니다.

가격 변동성

Is ATNX.Q's price volatile compared to industry and market?
ATNX.Q volatility
ATNX.Q Average Weekly Movement	339.2%
Biotechs Industry Average Movement	10.5%
Market Average Movement	5.7%
10% most volatile stocks in US Market	15.4%
10% least volatile stocks in US Market	2.8%

안정적인 주가: ATNX.Q 의 주가는 지난 3개월 동안 변동성이 심했습니다.

시간에 따른 변동성: ATNX.Q 의 주간 변동성은 지난 1년 동안 167% 에서 339% 로 증가했습니다.

회사 소개

설립	직원	CEO	웹사이트
2003	275	Johnson Lau	www.athenex.com

Athenex, Inc. 기본 사항 요약

Athenex 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ATNX.Q 기본 통계
시가총액	US$131.68k
수익(TTM)	-US$97.98m
수익(TTM)	US$102.82m

0.0x

P/S 비율

0.0x

P/E 비율

ATNX.Q 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ATNX.Q 손익 계산서(TTM)
수익	US$102.82m
수익 비용	US$76.12m
총 이익	US$26.70m
기타 비용	US$124.68m
수익	-US$97.98m

최근 보고된 수익

Dec 31, 2022

다음 수익 날짜

n/a

주당 순이익(EPS)	-11.31
총 마진	25.97%
순이익 마진	-95.29%
부채/자본 비율	-511.7%

ATNX.Q 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

ATNX.Q 주식 개요

보상

위험 분석

Athenex, Inc. 경쟁사

OTCPK:PKBO

US$198.9k

OTCPK:ACOR.Q

US$316.7k

OTCPK:ATHX.Q

US$185.2k

OTCPK:ENDV

US$595.2k

가격 내역 및 성능

최근 뉴스 및 업데이트

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Recent updates

Athenex, Inc. Announces the Separation of Joe Annoni as Assistant Chief Restructuring Officer

Nasdaq to Delist the Common Stock of Athenex

Athenex, Inc.(OTCPK:ATNX.Q) dropped from NASDAQ Composite Index

Athenex, Inc. announced delayed 10-Q filing

Nasdaq Staff Determines Athenex's Common Stock to be Delisted from Nasdaq as a Result of the Chapter 11 Case

Athenex, Inc.(NasdaqGS:ATNX) dropped from S&P TMI Index

Motion for Asset Sale Filed by Athenex, Inc.

Athenex Receives Letter from the Listing Qualifications Staff of the Nasdaq as the Company No Longer Meets Nasdaq Listing Rule 5450(b)(3)(C)

Athenex Announces Reverse Stock Split

Athenex Announces MHRA Decision on Oral Paclitaxel

Athenex, Inc. Announces Quantum Leap Healthcare Collaborative Reports Positive Trial Result of I-SPY2 Trial for Oral Paclitaxel in Combination with PD-1 and Carboplatin in Neoadjuvant Breast Cancer

Price target decreased to US$2.17

Insufficient new directors

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Athenex, Inc. to Report Q3, 2022 Results on Nov 03, 2022

Athenex Receives Written Notification from Nasdaq Stating the Company Had Not Regained Compliance with the Rule and Was Ineligible to Obtain A Second 180 Calendar Day Period to Regain Compliance

Athenex, Inc. has completed a Follow-on Equity Offering in the amount of $29.995333 million.

Athenex prices $30M in stock and warrants offering

Dr. Reddy's, Intas Reportedly in Talks to Buy Athenex

Athenex surges 70% as Dr Reddy's and Intas race to form buyout deal

Second quarter 2022 earnings released: US$0.21 loss per share (vs US$0.33 loss in 2Q 2021)

Athenex GAAP EPS, revenue misses estimates

Athenex, Inc. to Report Q2, 2022 Results on Jul 28, 2022

TiHe Capital (Beijing) Co. Ltd. agreed to acquire Chongqing Taihao Pharmaceutical Co., Ltd. and Athenex Pharmaceuticals (Chongqing) Limited from Athenex, Inc. (NasdaqGS:ATNX) for CNY 124 million.

Athenex to sell its China API business for $19M

Athenex, Inc. Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy to Lead Its Clinical Development, Clinical Operations, and Regulatory Affairs Functions

Insufficient new directors

Athenex, Inc. Provides Sales Guidance for the Full Year 2022

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Insufficient new directors

Athenex, Inc. to Report Q1, 2022 Results on May 10, 2022

Price target decreased to US$4.50

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Refractory Lymphoma and Leukemia at the 2022 Transplantation & Cellular Meetings of ASTCT and CIBMTR

Kim Campbell Not to Stand for Re-Election to the Athenex Board of Directors At the 2022 Annual Meeting of Stockholders

Price target decreased to US$4.50

Consensus forecasts updated

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to US$5.50

Price target increased to US$6.67

Athenex Announces Appoints Joe Annoni as Chief Financial Officer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

Athenex, Inc. Announces UK MHRA Validation of the Marketing Authorization Application for Oral Paclitaxel and Encequidar for Review

Athenex to Present Subgroup Analysis from Phase 3 Study of Oral Paclitaxel Plus Encequidar (KX-ORAX-001) in Metastatic Breast Cancer At SABCS 2021

Independent Director recently bought US$61k worth of stock

Third quarter 2021 earnings released: US$0.33 loss per share (vs US$0.44 loss in 3Q 2020)

Independent Director recently bought US$161k worth of stock

Athenex: Is This Stock A Buy, Sell, Or Hold? It's A Hold.

Chief Financial Officer Randoll Sze has left the company

Second quarter 2021 earnings released: US$0.33 loss per share (vs US$0.50 loss in 2Q 2020)

Consensus EPS estimates fall to -US$1.31

Price target decreased to US$7.50

Athenex, Inc. Presents Data on Oral Docetaxel and Oral Paclitaxel at ASCO2021 Virtual Scientific Program

Athenex, Inc. Announces Klisyri® (Tirbanibulin) Receives Positive Chmp Opinion from the European Medicines Agency (Ema) for the Treatment of Actinic Keratosis of the Face or Scalp

Athenex, Texas Children’s Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine Present New Clinical Data on GD2 CAR-NKTCells in Neuroblastoma at ASGCT Annual Meeting

First quarter 2021 earnings released: US$0.27 loss per share (vs US$0.24 loss in 1Q 2020)

Independent Director exercised options to buy US$230k worth of stock.

Consensus EPS estimates increase to -US$1.42

Athenex, Inc. Reaffirms Sales Guidance for the Year 2021